m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04198)
Name
SXC-2023
Status
Phase 2
TTD Drug ID
D1KO3P
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Cystine/glutamate transporter (SLC7A11)
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cystine/glutamate transporter (SLC7A11) is a therapeutic target for SXC-2023. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of SXC-2023 through regulating the expression of Cystine/glutamate transporter (SLC7A11). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cystine/glutamate transporter (SLC7A11) is a therapeutic target for SXC-2023. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SXC-2023 through regulating the expression of Cystine/glutamate transporter (SLC7A11). [2], [3]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cystine/glutamate transporter (SLC7A11) is a therapeutic target for SXC-2023. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SXC-2023 through regulating the expression of Cystine/glutamate transporter (SLC7A11). [1], [2]
NF-kappa-B-activating protein (NKAP)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cystine/glutamate transporter (SLC7A11) is a therapeutic target for SXC-2023. The NF-kappa-B-activating protein (NKAP) has potential in affecting the response of SXC-2023 through regulating the expression of Cystine/glutamate transporter (SLC7A11). [2], [4]
YTH domain-containing protein 2 (YTHDC2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cystine/glutamate transporter (SLC7A11) is a therapeutic target for SXC-2023. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of SXC-2023 through regulating the expression of Cystine/glutamate transporter (SLC7A11). [2], [5]
References
Ref 1 The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma. Clin Transl Med. 2022 May;12(5):e778. doi: 10.1002/ctm2.778.
Ref 2 US patent application no. 6,498,035, Antisense modulation of MEKK3 expression.
Ref 3 N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nat Commun. 2022 May 13;13(1):2672. doi: 10.1038/s41467-022-30217-7.
Ref 4 RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m(6)A-dependent manner. Cell Death Dis. 2022 Jan 21;13(1):73. doi: 10.1038/s41419-022-04524-2.
Ref 5 The m(6)A reader YTHDC2 inhibits lung adenocarcinoma tumorigenesis by suppressing SLC7A11-dependent antioxidant function. Redox Biol. 2021 Jan;38:101801. doi: 10.1016/j.redox.2020.101801. Epub 2020 Nov 18.